# Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

> **NCT07325292** · PHASE3 · RECRUITING · sponsor: **Sanofi** · enrollment: 160 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Frexalimab
- **DRUG:** Frexalimab
- **DRUG:** MRI contrast-enhancing preparations

## Key facts

- **NCT ID:** NCT07325292
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-14
- **Primary completion:** 2027-07-15
- **Final completion:** 2028-11-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07325292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07325292, "Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT07325292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*